Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study

Journal of the American Academy of Dermatology

Volumn 47, Issue 3, 2002, Pages 390-398

  Geisse, John K ^a   Rich, Phoebe ^b   Pandya, Amit ^c   Gross, Kenneth ^d   Andres, Kara ^e   Ginkel, Angie ^e   Owens, Mary ^e  

^a Solano Dermatology Associates   (United States)

^b Northwest Cutaneous Research Specialists   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Skin Surgery Medical Group   (United States)

^e 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY;

EID: 0036737628     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.126215     Document Type: Article

References (22)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30:774-8.
3. Puizina-Ivi N, Matokovi B, Gluni I, Maslovara S, Vela-Ljubi J. Histopathologic variants of basal cell carcinoma correlation with sex, age and localization. J Med Syst 1999;23:389-400.
4. Bastiaens MT, Hoefinagel JJ, Bruijn JA, Westendorp RGJ, Vermeer BJ, Bavinck JNB. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinomas indicate different types of tumors. J Invest Dermatol 1998;110:880-4.
5. Jaramillo-Ayerbe F. Cryosurgery in difficult to treat basal cell carcinoma. Int J Dermatol 2000;39:223-9.
6. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma: a possible indication of differing causes. Arch Dermatol 1997;133:593-6.
7. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 1: overview; Part 2: curettage-electrodesiccation. J Dermatol Surg Oncol 1991;17:713-8, 720-6.
8. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision. J Dermatol Surg Oncol 1992;18:471-6.
9. Robinson JK. Risk of developing another basal cell carcinoma: a 5-year prospective study. Cancer 1987;60:118-20.
10. Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream (Aldara). Exp Opin Invest Drugs 1998;7:437-50.
11. Edwards L, Whiting D, Rogers D, Luck K, Smiles KA. The effect of intralesional interferon gamma on basal cell carcinomas. J Am Acad Dermatol 1990;22:496-500.
12. Edwards L, Tucker S, Perednia D, Smiles KA, Taylor EL, Tanner DJ, et al. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. Arch Dermatol 1990;126:1029-32.
13. Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990;23:694-700.
14. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;416:1002-7.
15. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988;124:869-71.
16. Holmkvist KA, Rogers GS, Dahl PR. Incidence of residual basal cell carcinoma in patients who appear tumor free after biopsy. J Am Acad Dermatol 1999;41:600-5.
17. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of a superficial basal cell nevus syndrome patient. Dermatol Surg 2000;26:577-9.
18. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
19. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. Br J Dermatol 1999;141:415-23.
20. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135:1177-83.
21. Robinson JK, Fisher SG. Recurrent basal cell carcinoma after incomplete resection, Arch Dermatol 2000;136:1318-24.
22. Chiller K, Passaro D, McCalmont T, Vin-Christian K. Efficacy of curettage before excision in clearing surgical margins of non-melanoma skin cancer. Arch Dermatol 2000;136:1327-32.